Course: Moving the Needle: Adopting New Evidence Into the Lower-Risk Myelodysplastic Syndrome Treatment Paradigm
Released: 0000-00-00
Program Description
Click to Go to the Event Registration
While the frontline treatment landscape expands for lower-risk myelodysplastic syndrome (LR-MDS), providers are faced with new opportunities and challenges to individualizing care.
Join leading LR-MDS experts in this research-informed webinar, which will divulge real-world challenges to integrating novel LR-MDS therapies and mitigating treatment-related adverse events identified through a recent hematology/oncology provider survey. The expert faculty will then take the audience through complex clinical cases, sharing real-world perspectives with various "what if" scenarios to explore key nuances of decision-making regarding dose titration and adverse event management.
Wrapping up with a live question and answer session, this webinar is designed to equip you with evidence-based strategies to individualize frontline treatment plans for LR-MDS patients.
Agenda
I. Evaluating Real-World Barriers to Evidence-Based Integration of Novel Therapies for Lower-risk Myelodysplastic Syndrome (LR-MDS)
II. Latest Clinical Evidence and Guideline Recommendations for Frontline Treatment and Management of LR-MDS
III. Expert Approaches to Complex LR-MDS Patient Cases
Interprofessional Strategies for Individualized Frontline Treatment Selection
Expert Recommendations on Optimal Treatment Dosing, Titration, and Monitoring
Multidisciplinary Strategies for Prevention, Prompt Recognition, and Management of Adverse Events Associated With Novel LR-MDS Treatments
IV. Question and Answer Session
Intended Audience
Hematologists/oncologists and their clinical teams, including NPs/PAs, pharmacists, nurses, nurse navigators, and case managers caring for patients with LR-MDS
Commercial Supporter
This activity is supported by an educational grant from Bristol Myers Squibb.
Learning Objectives
Upon completion of this activity, learners should be able to:
Assess real-world data to identify barriers to optimal integration of novel therapies for frontline lower-risk myelodysplastic syndromes (LR-MDS) among hematology/oncology providers, including barriers unique to specific practice settings and disciplines
Evaluate the latest clinical safety and efficacy data for newly approved frontline LR-MDS therapies
Apply evidence-based strategies for effective integration, dosing, titration, and monitoring of novel therapies for LR-MDS
Employ multidisciplinary approaches for prevention, prompt recognition and management of adverse events with novel frontline LR-MDS treatments
View Full Course